Valuation: Patrys Limited

Market Cap 24.66M 16.99M 14.87M 13.71M 12.81M 24.13M 1.61B 165M 63.8M 793M 63.8M 62.4M 2.75B P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 23.92M 16.48M 14.42M 13.29M 12.42M 23.41M 1.56B 160M 61.88M 770M 61.88M 60.52M 2.67B EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 day-5.13%
1 week-17.78%
Current month-17.78%
1 month-11.90%
3 months+27.59%
6 months+23.33%
Current year+32.14%
1 week 0.04
Extreme 0.037
0.04
1 month 0.04
Extreme 0.037
0.05
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.012
0.05
3 years 0.01
Extreme 0.012
0.14
5 years 0.01
Extreme 0.012
0.74
10 years 0.01
Extreme 0.012
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Chief Operating Officer - 01/06/2012
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap.
11/08/23Expiration

Chief Executive Officer

3,283 0.0002%
11/08/23Expiration

Chief Executive Officer

396,132 0.0193%
06/12/21Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
-5.13%-17.78%+208.33%-69.17% 17.95M
+0.13%+1.50%+63.86%+123.95% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+3.33%+3.71%-11.68%-11.82% 23.07B
+1.32%+9.33%+5.28%+419.80% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+5.01%+31.23%-32.10% 15.94B
-0.89%+4.57%+24.30%+185.83% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +2.74%+4.82%+64.41%+114.66% 22.63B
Weighted average by Cap. +3.42%+7.62%+54.18%+128.94%

Financials

2024 2025
Net sales 1.39M 960K 841K 775K 724K 1.36M 90.78M 9.32M 3.61M 44.85M 3.61M 3.53M 155M 829K 571K 500K 460K 430K 811K 53.95M 5.54M 2.14M 26.65M 2.14M 2.1M 92.36M
Net income -3.54M -2.44M -2.13M -1.97M -1.84M -3.46M -230M -23.65M -9.15M -114M -9.15M -8.95M -395M -3.01M -2.08M -1.82M -1.67M -1.56M -2.95M -196M -20.13M -7.79M -96.94M -7.79M -7.62M -336M
Net Debt -2.24M -1.54M -1.35M -1.25M -1.16M -2.19M -146M -14.97M -5.8M -72.08M -5.8M -5.67M -250M -742K -511K -448K -413K -386K -726K -48.34M -4.96M -1.92M -23.88M -1.92M -1.88M -82.76M
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
29/06/26 A$0.0370 -5.13% 664,981
26/06/26 A$0.0390 -4.88% 1,507,291
25/06/26 A$0.0410 0.00% 605,971
24/06/26 A$0.0410 -6.82% 2,193,426
23/06/26 A$0.0440 -2.22% 254,187